Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M L Rothenberg

Showing results (11-20 of 62) with videos related to

Pageof 7
Sort By:
Seminars in Oncology|December 22, 1999
Topoisomerase I inhibitors in the treatment of colorectal cancerM L Rothenberg, C D Blanke
Investigational New Drugs|January 1, 1994
Multidrug resistance in cancer chemotherapyN H Patel, M L Rothenberg
Lancet (London, England)|August 31, 1991
Medical oncology in the 1990sB A Chabner, M L Rothenberg
Journal of Cancer Research and Clinical Oncology|January 1, 1993
Summary of a joint meeting between the Southwest Oncology Group and the Japanese clinical trials consortiumM L Rothenberg, C A Coltman, M Fukushima
Oncology (Williston Park, N.Y.)|November 7, 1999
DNA topoisomerase I-targeting drugs as radiation sensitizersA Y Chen, H Choy, M L Rothenberg
Journal of Cancer Research and Clinical Oncology|January 1, 1994
Gastric and esophageal cancers: perspectives from a U.S.-Japan meeting. Hawaii, February 6-7, 1993M L Rothenberg, M Fukushima, C A Coltman
Stem Cells (Dayton, Ohio)|August 7, 1999
New drugs on the horizon: matrix metalloproteinase inhibitorsM L Rothenberg, A R Nelson, K R Hande
Journal of Cancer Research and Clinical Oncology|January 1, 1997
Bone and soft tissue sarcomas: summary of the Third United States/Japan Clinical Trials Summit (Seattle, Washington)A Uchida, M Fukushima, M L Rothenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2000
Matrix metalloproteinases: biologic activity and clinical implicationsA R Nelson, B Fingleton, M L Rothenberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2016
Pragmatic randomized clinical trials: a proposal to enhance evaluation of new cancer therapies with early signs of exceptional activityM Koehler, E T Donnelly, D Kalanovic, et al.
Pageof 7

Showing results (11-20 of 62) with videos related to

Sort By:
Pageof 7
Seminars in Oncology|December 22, 1999
Topoisomerase I inhibitors in the treatment of colorectal cancerM L Rothenberg, C D Blanke
Investigational New Drugs|January 1, 1994
Multidrug resistance in cancer chemotherapyN H Patel, M L Rothenberg
Lancet (London, England)|August 31, 1991
Medical oncology in the 1990sB A Chabner, M L Rothenberg
Journal of Cancer Research and Clinical Oncology|January 1, 1993
Summary of a joint meeting between the Southwest Oncology Group and the Japanese clinical trials consortiumM L Rothenberg, C A Coltman, M Fukushima
Oncology (Williston Park, N.Y.)|November 7, 1999
DNA topoisomerase I-targeting drugs as radiation sensitizersA Y Chen, H Choy, M L Rothenberg
Journal of Cancer Research and Clinical Oncology|January 1, 1994
Gastric and esophageal cancers: perspectives from a U.S.-Japan meeting. Hawaii, February 6-7, 1993M L Rothenberg, M Fukushima, C A Coltman
Stem Cells (Dayton, Ohio)|August 7, 1999
New drugs on the horizon: matrix metalloproteinase inhibitorsM L Rothenberg, A R Nelson, K R Hande
Journal of Cancer Research and Clinical Oncology|January 1, 1997
Bone and soft tissue sarcomas: summary of the Third United States/Japan Clinical Trials Summit (Seattle, Washington)A Uchida, M Fukushima, M L Rothenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2000
Matrix metalloproteinases: biologic activity and clinical implicationsA R Nelson, B Fingleton, M L Rothenberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2016
Pragmatic randomized clinical trials: a proposal to enhance evaluation of new cancer therapies with early signs of exceptional activityM Koehler, E T Donnelly, D Kalanovic, et al.
Pageof 7